Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another ...

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

T-Mobile US Inc. has rolled back policies related to diversity, equity, and inclusion to appease the chairman of the Federal ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Health-care companies rose as deal activity offset more health-insurance controversy. Merck struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive ...